U.K. likely to pay for Avastin despite another NICE rejection

Eric Palmer Regulators have again turned down Roche's ($ RHHBY) cancer drug Avastin for payment by the National Health System (NHS), this time for use on a recurrent, advanced ...

Sanofi embarks on doc-training in Morocco to boost diabetes, epilepsy care

Tracy Staton In established markets, Big Pharma targets doctors to boost sales. In emerging markets, drugmakers train them. Directly. Several of the globe's biggest pharma companies ...

Dual-eligibles bill sets up another pharma fight over Medicare rebates

Tracy Staton Democratic lawmakers in both houses of Congress are backing a new bill extending Medicaid-style rebates to low-income Medicare patients, saying the provision would save ...

Swiss biotech raises $50.6M to further hearing-loss drugs

Emily Mullin Swiss biotech Auris Medical has raised $ 50.6 million in a Series C round of financing to advance its two major therapeutics for the treatment of inner ear disorders. The ...

OxyContin patent expires Tuesday but FDA under pressure to stall generics

Eric Palmer Purdue's original patent on the superpotent and often abused painkiller OyxContin expires tomorrow, and drugmakers like Teva Pharmaceutical Industries ($ TEVA) are ...

CEO Chris Viehbacher steers Sanofi clear of drugs for Alzheimer’s disease

Eric Palmer Any company that can develop a drug even partially effective against Alzheimer's disease will strike a gold mine. One analyst estimates the opportunity to be $ 20 ...

Europe wants more restrictions on Servier’s Protelos

Eric Palmer France's Servier is under renewed scrutiny from European regulators. Citing heart risks, a committee of the European Medicines Agency (EMA) has recommended further ...

Vivus investor says FDA move on Qsymia isn’t enough

Tracy Staton At least one Vivus ($ VVUS) shareholder isn't convinced that loosening FDA restrictions on a new obesity pill will fuel sales in any significant way. First Manhattan, ...

Syros Pharma snags $30M funding deal to target master switches of cancer genes

Ryan McBride With licenses to breaking discoveries from labs affiliated with MIT and Harvard, Syros Pharmaceuticals has raised $ 30 million in a Series A round of financing from top ...

With patent clock ticking, Amgen plans to shutter Epogen plant

Idled Longmont plant will cost some jobs, but other on-site functions will stay By Tracy Staton In a major milestone for its anemia franchise, Amgen ($AMGN) is preparing to idle production ...

Isis California facility gains GMP certification from EMA

PBR Staff Writer Isis Pharmaceuticals has received Good Manufacturing Practices (GMP) certification to its manufacturing facility located in Carlsbad, California, US, from the EMA for ...
Page 32 of 32« First...1020...2829303132
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS